So far, serious side effects havent been common, but heres what an early phase 2 study has shown: Pancreatitis: Happened in about 0.4% of people in the study Gallbladder problems: Reported in about 1.1% of participants Heart rhythm changes: Seen more often with retatrutide, about 6% compared to 3% with placebo Liver enzyme changes: Around 1% of participants had increases, but overall liver health stayed stable These results suggest a low but real chance of serious issues such as pancreatitis, gallbladder problems, severe GI events, and allergic reactions
If depression symptoms emerge, inform your healthcare provider immediately rather than stopping tirzepatide abruptly, which can cause rebound weight gain and mood instability
Endocrine disruptors
What to avoid Certain combinations should be avoided or approached with extreme caution
Eduardo Grunvald, medical director for UC San Diego's Center for Advanced Weight Management
Betalningsinformation Vi accepterar fr nrvarande kredit- och betalkort frn Visa, Mastercard och American Express
